Julia Perkins Smith

425 total citations · 1 hit paper
12 papers, 253 citations indexed

About

Julia Perkins Smith is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Julia Perkins Smith has authored 12 papers receiving a total of 253 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Julia Perkins Smith's work include Advanced Breast Cancer Therapies (6 papers), Protein Degradation and Inhibitors (5 papers) and Ovarian cancer diagnosis and treatment (4 papers). Julia Perkins Smith is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Protein Degradation and Inhibitors (5 papers) and Ovarian cancer diagnosis and treatment (4 papers). Julia Perkins Smith collaborates with scholars based in United States, Japan and Italy. Julia Perkins Smith's co-authors include Yaroslav Shparyk, Ross Stewart, Jonathan A. Ledermann, Xiaoxi Zhang, Nicoletta Colombo, Joohyuk Sohn, Elena Poddubskaya, Keiichi Fujiwara, Leslie M. Randall and Michael J. Birrer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Julia Perkins Smith

11 papers receiving 250 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

2021 160 citations Bradley J. Monk, Nicoletta Colombo et al. The Lancet Oncology profile →

Peers

Julia Perkins Smith

ONCOL

IMMUN

PRM

Valerie Heong Singapore

Mengdi He China

Eva María Guerra Alia Spain

E. Hitt Nichols United States

Hasan Mirza United Kingdom

Clare Bartos United Kingdom

Alison Freimund Australia

Sabine Coppieters United States

Moran Yang China

Floriana Camarda Italy

Valerie Heong Singapore

Julia Perkins Smith

135 ×0.9

ONCOL

107 ×1.2

74 ×1.0

52 ×0.7

IMMUN

32 ×0.6

PRM

Citations per year, relative to Julia Perkins Smith Julia Perkins Smith (= 1×) peers Valerie Heong

Countries citing papers authored by Julia Perkins Smith

Since Specialization

Citations

This map shows the geographic impact of Julia Perkins Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Perkins Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Perkins Smith more than expected).

Fields of papers citing papers by Julia Perkins Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Perkins Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Perkins Smith. The network helps show where Julia Perkins Smith may publish in the future.

Co-authorship network of co-authors of Julia Perkins Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Perkins Smith. A scholar is included among the top collaborators of Julia Perkins Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Perkins Smith. Julia Perkins Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Hilton, John, A. Jo Chien, Colombe Chappey, et al.. (2025). Abstract P4-12-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results. Clinical Cancer Research. 31(12_Supplement). P4–12. 4 indexed citations

Tan, Weiwei, et al.. (2025). Abstract P4-08-13: Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination With Cyclin-Dependent Kinase (CDK)4/6 Inhibitors and Everolimus. Clinical Cancer Research. 31(12_Supplement). P4–8. 2 indexed citations

Campone, Mario, X. Cynthia, Michelino De Laurentiis, et al.. (2024). Abstract PO1-19-12: VERITAC-2: a phase 3 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Cancer Research. 84(9_Supplement). PO1–19. 1 indexed citations

Hamilton, Erika, X. Cynthia, Michelino De Laurentiis, et al.. (2024). VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future Oncology. 20(32). 2447–2455. 40 indexed citations

Wander, Seth A., Erika Hamilton, Mario Campone, et al.. (2024). Abstract PO2-20-03: VERITAC-3: A randomized phase 3 study, with a lead-in, of first-line vepdegestrant + palbociclib vs letrozole + palbociclib in estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. Cancer Research. 84(9_Supplement). PO2–20. 2 indexed citations

Campone, Mario, X. Cynthia, Michelino De Laurentiis, et al.. (2023). VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.. Journal of Clinical Oncology. 41(16_suppl). TPS1122–TPS1122. 30 indexed citations

Layman, Rachel M., Katarzyna J. Jerzak, John Hilton, et al.. (2023). TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.. Journal of Clinical Oncology. 41(16_suppl). TPS1121–TPS1121. 6 indexed citations

Monk, Bradley J., Nicoletta Colombo, Amit M. Oza, et al.. (2021). Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. The Lancet Oncology. 22(9). 1275–1289. 160 indexed citations breakdown →

Pujade-Lauraine, Éric, Jonathan A. Ledermann, Amit M. Oza, et al.. (2021). 225 Avelumab alone in platinum-resistant/refractory ovarian cancer: selected biomarker analyses from the JAVELIN Ovarian 200 trial. A210.1–A210. 1 indexed citations

10.

Pujade-Lauraine, Éric, Jonathan A. Ledermann, Amit M. Oza, et al.. (2021). 229 Avelumab combined with pegylated liposomal doxorubicin in platinum-resistant/refractory ovarian cancer: biomarker analyses from JAVELIN Ovarian 200. A210.2–A211. 1 indexed citations

11.

Ledermann, Jonathan A., Nicoletta Colombo, Amit M. Oza, et al.. (2020). 1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial. A1.1–A1. 5 indexed citations

12.

Smith, Julia Perkins, Georg A. Holländer, Paul Predki, et al.. (2016). Emerging platform bioprocesses for viral vectors and gene therapies. Oxford University Research Archive (ORA) (University of Oxford). 14. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact